IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 35,808 shares of the medical research company’s stock after selling 670 shares during the period. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $7,571,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. First Foundation Advisors boosted its position in shares of IQVIA by 3.8% during the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after buying an additional 43 shares during the period. Team Hewins LLC boosted its position in IQVIA by 5.0% during the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after acquiring an additional 46 shares during the period. Invera Wealth Advisors LLC grew its stake in shares of IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares in the last quarter. Covestor Ltd increased its holdings in shares of IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the period. Finally, Oregon Public Employees Retirement Fund raised its stake in shares of IQVIA by 0.3% during the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $236.23 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The firm’s 50 day simple moving average is $241.06 and its 200-day simple moving average is $233.67. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The company has a market cap of $43.06 billion, a P/E ratio of 32.27, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on IQV. The Goldman Sachs Group began coverage on shares of IQVIA in a research report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Morgan Stanley increased their price objective on shares of IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Robert W. Baird upped their target price on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Truist Financial increased their price target on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Evercore ISI upped their price objective on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $267.00.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.